Trial Profile
Delamanid, a New Drug for Multi-Drug Resistant Tuberculosis (MDR-TB), and Efavirenz Do Not Show Clinically Relevant Drug Interactions in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Sep 2012
Price :
$35
*
At a glance
- Drugs Delamanid (Primary) ; Efavirenz
- Indications HIV infections; Tuberculosis
- Focus Pharmacokinetics
- 18 Sep 2012 New trial record